Photoallergic contact dermatitis in Europe by Kerr, Alastair
University of Dundee
DOCTOR OF MEDICINE








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
DOCTOR OF MEDICINE




Conditions for Use and Duplication
Copyright of this work belongs to the author unless otherwise identified in the body of the thesis. It is permitted
to use and duplicate this work only for personal and non-commercial research, study or criticism/review. You
must obtain prior written consent from the author for any other use. Any quotation from this thesis must be
acknowledged using the normal academic conventions. It is not permitted to supply the whole or part of this
thesis to any other person or to post the same on any website or other online location without the prior written
consent of the author. Contact the Discovery team (discovery@dundee.ac.uk) with any queries about the use
or acknowledgement of this work.
  
 









Thesis presented for the degree of Doctor of Medicine 





List of Figures...................................................................................................... viii 
List of Tables........................................................................................................ xii 
List of abbreviations............................................................................................ xv 
Acknowledgements.............................................................................................. xvi 
Declaration........................................................................................................... xvii 
Contribution to collaborative studies................................................................xviii 
List of relevant publications............................................................................... xx 
Abstract................................................................................................................ xxi 
 
Chapter 1. Introduction...................................................................................... 1 
1.1 Photoallergic contact dermatitis and historical aspects................................... 1 
1.1.1 Definition............................................................................................... 1 
1.1.2 Differential diagnosis............................................................................ 2 
1.1.3 Incidence................................................................................................3 
1.1.4 Historical photoallergens....................................................................... 4 
1.1.4.1 Antimicrobial agents................................................................... 4 
1.1.4.2 Fragrances................................................................................... 5 
1.1.4.3 Veterinary products..................................................................... 6 
1.1.4.4 Medications................................................................................. 6 
1.1.4.5 Inclusion of historical agents in PPT series................................ 7 
1.1.5 The Persistent Light Reactor................................................................. 7 
1.1.6 Mechanisms of PACD........................................................................... 8 
1.1.7 Systemic photoallergy........................................................................... 10 
1.2 Photopatch testing........................................................................................... 12 
1.2.1 Methodology.........................................................................................  12 
1.2.2 PPT in photosensitive subjects.............................................................. 15    
1.2.3 Divergent PPT methodologies............................................................... 15 
1.2.4 Wavelengths for irradiation................................................................... 17 
1.2.5 Dose for irradiation................................................................................19 
1.2.6 Timing of photopatch application and readings.................................... 19 
1.2.7 Recording results................................................................................... 20 
1.2.8 Interpretation of results..........................................................................20 
1.2.9 Standardisation...................................................................................... 22  
1.3 Current Photoallergens.................................................................................... 23 
1.3.1 Organic UV absorbers........................................................................... 23 
1.3.1.1 History of development............................................................... 23 
1.3.1.2 Regulation of sunscreens in Europe............................................ 24 
iii 
1.3.1.3 Agent classes and reports of PACD and ACD............................ 25 
“Older” organic UV absorbers....................................................... 27 
Salicylates................................................................................. 28 
Cinnamates................................................................. .............. 28 
Octocrylene............................................................................... 30 
Phenylbenzimidazole sulfonic acid........................................... 30 
Para-aminobenzoic acid (PABA).............................................. 31 
Benzophenones.......................................................................... 32 
Camphor derivatives................................................................. 34 
Dibenzoylmethanes................................................................... 34 
“Newer” organic UV absorbers...................................................... 36  
UVB absorbers.......................................................................... 37 
UVA absorbers.......................................................................... 39 
UVB and UVA absorbers.......................................................... 41 
1.3.2 Topical NSAIDs.................................................................................... 46 
1.3.3 Photosafety testing of potential photoallergens..................................... 50 
1.4 Summary.......................................................................................................... 52 
1.5 References....................................................................................................... 53 
 
Chapter 2. An occupational outbreak of photoallergy to carprofen.............. 71 
2.1 Introduction..................................................................................................... 71 
2.1.1 Background........................................................................................... 71 
2.1.2 Carprofen............................................................................................... 71 
2.1.3 The Patients........................................................................................... 72 
2.1.4 Objective................................................................................................73 
2.2 Methods........................................................................................................... 74 
2.2.1 PPT to carprofen.................................................................................... 74 
2.2.2 Rationale for strength of carprofen used............................................... 75 
2.2.3 Control subjects..................................................................................... 75 
2.3 Results............................................................................................................. 77 
2.3.1 Initial PPT.............................................................................................. 77 
2.3.2 Additional PPT...................................................................................... 82 
2.3.3 Follow-up of patients 1 & 2.................................................................. 82 
2.3.4 Healthy volunteer controls.................................................................... 84 
2.3.5 Visit to the factory................................................................................. 84 
2.4 Discussion........................................................................................................ 86 
2.5 References....................................................................................................... 89 
 
Chapter 3. Chlorproethazine: A second photoallergen on the marketplace. 91 
3.1 Introduction..................................................................................................... 91 





3.2 Materials and Methods.................................................................................... 95 
iv 
3.2.1 Assessment of photostability................................................................. 95 
3.2.2 Phototoxic in-vitro studies..................................................................... 95 
3.2.3 Pilot PPT study...................................................................................... 96 
3.2.4 Extended PPT study.............................................................................. 97 
3.3 Results............................................................................................................. 99 
3.3.1 Assessment of photostability................................................................. 99 
3.3.2 Phototoxic in-vitro studies..................................................................... 101 
3.3.3 Pilot PPT study...................................................................................... 101 
3.3.4 Extended PPT study.............................................................................. 103 
3.4 Discussion........................................................................................................ 111 
3.5 References....................................................................................................... 115 
 
Chapter 4. A pilot irritancy study of organic ultraviolet absorbers............... 116 
4.1 Introduction..................................................................................................... 116 
4.1.1 Background........................................................................................... 116 
4.1.2 Factors influencing IRs..........................................................................116 
4.1.3 Determining optimum agent concentrations......................................... 117 
4.1.2 Objective................................................................................................118 
4.2 Methods........................................................................................................... 119 
4.2.1 Participants............................................................................................ 119 
4.2.2 PPT and test agents................................................................................ 120 
4.2.3 Study design and statistical methods..................................................... 123 
4.3 Results............................................................................................................. 125 
4.3.1 Analysed population.............................................................................. 125 
4.3.2 Number of reactions by ICDRG scale................................................... 126 
4.3.3 Number of reactions by erythema scale................................................ 128 
4.3.4 Agreement between ICDRG and erythema scales................................ 128 
4.3.5 Number of doubtful and weak positive ICDRG graded reactions by site 
and time.......................................................................................................... 129 
4.3.6 Number of doubtful and weak positive ICDRG graded reactions by UV 
absorber.......................................................................................................... 129 
4.4 Discussion........................................................................................................ 132 
4.4.1 Comparison with previous studies........................................................ 132 
4.4.2 Limitations of the study......................................................................... 133 
4.4.3 IRs and PPT........................................................................................... 134 
4.4.4 Determining IRs.................................................................................... 134 
4.4.5 The effect of UVA irradiation............................................................... 135 
4.4.6 Implications for the EMCPPTS............................................................. 136 
4.5 References....................................................................................................... 138 
 
Chapter 5. A survey of the availability of sunscreen absorbers in the UK.... 140 
5.1 Introduction..................................................................................................... 140 
5.2 Methods........................................................................................................... 142 
5.3 Results............................................................................................................. 144 
v 
5.4 Discussion....................................................................................................... 153 
5.4.1 Limitations............................................................................................. 153 
5.4.2 Comparison with the 2005 UK survey.................................................. 154 
5.4.3 Individual agents................................................................................... 155 
5.4.4 Inorganic reflectors................................................................................ 157 
5.5 References....................................................................................................... 159 
 
Chapter 6. The European multi-centre photopatch test study (EMCPPTS). 160 
6.1 Introduction..................................................................................................... 160 
6.1.1 The initiation meeting............................................................................160 
6.1.2 The centres.............................................................................................161 
6.1.3 Objectives.............................................................................................. 164 
6.2 Methods........................................................................................................... 165 
6.2.1 Inclusion and exclusion criteria............................................................. 165 
6.2.2 Investigation of subjects with marked UV Sensitivity.......................... 166 
6.2.3 Calibration of UVA meters................................................................... 166 
6.2.4 Photopatch test agents........................................................................... 166 
6.2.5 PPT methodology.................................................................................. 168 
6.2.5.1 Application of patches................................................................. 168 
 6.2.5.2 Timing of readings...................................................................... 169 
 6.2.5.3 Irradiation.................................................................................... 169 
 6.2.5.4 Photopatch readings.................................................................... 170 
 6.2.5.5 Collation of results...................................................................... 170 
 6.2.5.6 Interpretation of results............................................................... 173 
6.3 Results............................................................................................................. 174 
6.3.1 PACD reactions..................................................................................... 176 
6.3.1.1 PACD reactions at different timepoints...................................... 183 
6.3.2 ACD reactions....................................................................................... 188 
6.3.3 Photoaugmentation of ACD.................................................................. 192 
6.3.4 Photoinhibition of ACD........................................................................ 192 
6.3.5 Irritant reactions (IR)............................................................................. 192 
6.3.6 Subjects with multiple reaction patterns................................................192 
6.3.7 Photopatch application time.................................................................. 195 
6.3.8 Gender................................................................................................... 195 
6.3.9 Age........................................................................................................ 196 
6.3.10 Diagnosis............................................................................................. 198 
6.3.11 Photosensitive subjects........................................................................ 199 
6.3.12 Indication for testing........................................................................... 200 
6.3.13 Regional patterns of reactions............................................................. 202 
6.3.14 Cross reactions.................................................................................... 207 
6.3.15 Testing to own agents.......................................................................... 212 
6.3.15.1 PACD reactions......................................................................... 212 
 6.3.15.2 ACD reactions........................................................................... 213 
6.4 Discussion........................................................................................................ 214 
vi 
6.4.1 PACD to test agents.............................................................................. 214 
6.4.1.1 Ketoprofen................................................................................... 214 
 6.4.1.2 Etofenamate................................................................................. 216 
 6.4.1.3 Octocrylene................................................................................. 218 
 6.4.1.4 Benzophenone-3.......................................................................... 218 
 6.4.1.5 Butyl methoxydibenzoylmethane................................................ 219 
 6.4.1.6 The cinnamates and 4-methylbenzylidene camphor................... 219 
 6.4.1.7 The salicylates and phenylbenzimidazole sulfonic acid.............. 220 
 6.4.1.8 Piroxicam, ibuprofen and diclofenac...........................................220 
 6.4.1.9 The “newer” organic UV absorbers............................................ 221 
6.4.2 ACD reactions....................................................................................... 222 
6.4.3 Photoaugmentation, photoinhibition and irritancy................................ 224 
6.4.4 Regional patterns of PACD................................................................... 224 
6.4.5 Photopatch application time.................................................................. 225 
6.4.6 Timing of readings................................................................................ 226 
6.4.7 Gender................................................................................................... 226 
6.4.8 Age........................................................................................................ 227 
6.4.9 Diagnosis............................................................................................... 227 
6.4.10 PPT in photosensitive subjects............................................................ 228 
6.4.11 Indications for testing.......................................................................... 228 
6.4.12 Testing additional “own agents”......................................................... 229 
6.4.13 Study limitations.................................................................................. 230 
6.5 Conclusions..................................................................................................... 232   
6.6 References....................................................................................................... 233 
 
Chapter 7. Conducting the EMCPPTS............................................................. 235 
7.1 Why perform the EMCPPTS?......................................................................... 235 
7.2 The EMCPPTS initiation meeting................................................................... 236 
7.3 Refining the protocol and proforma................................................................ 238 
7.4 Data handling................................................................................................... 239 
7.5 Calibration of UVA meters............................................................................. 240 
7.6 Delivery of agents............................................................................................ 241 
7.7 Application for ethical approval...................................................................... 242 
7.8 Application for Research and Development approval..................................... 245 
7.9 A major protocol violation.............................................................................. 248 
7.10 Funding the EMCPPTS................................................................................. 249 
7.11 Other issues around conducting the EMCPPTS............................................ 250 
7.12 References..................................................................................................... 255 
 
Chapter 8. A new European Baseline photopatch test series.......................... 256 
8.1 A second Amsterdam meeting in February 2012............................................ 256 
8.2 The agents in a new European Baseline series............................................... 257 
8.3 The agents in an “additional” European photopatch test series ..................... 260 
8.4 Agents excluded from either photopatch test series........................................ 264 
vii 
8.5 The future of the European PPT series’.......................................................... 266 
 
Chapter 9. Conclusions and Future Directions................................................ 267 
 
Appendices........................................................................................................... 275 
Appendix 1. The 26 agents currently listed in Annex VII of the European 
Commission cosmetic ingredients database, with their maximum permitted 
concentrations and notification of inclusion in the EMCPPTS or otherwise 
Appendix 2. The final version of the EMCPPTS protocol  
Appendix 3. The final version of the EMCPPTS proforma 




List of Figures 
  Page 
Figure 1.1. The process of conducting PPT 13/14 
Figure 1.2. The molecular structure of homosalate and ethylhexyl 
salicylate  
28 
Figure 1.3. The molecular structure of ethylhexyl methoxycinnamate 
and isoamyl-p-methoxycinnamate 
29 
Figure 1.4. The molecular structure of octocrylene 30 
Figure 1.5. The molecular structure of phenylbenzimidazole sulfonic 
acid 
30 
Figure 1.6. The molecular structure of PABA and ethylhexyldimethyl 
PABA 
32 
Figure 1.7. The molecular structure of benzophenone-3 and 
benzophenone-4 
33 
Figure 1.8. The molecular structure of 4-methylbenzylidene camphor 34 
Figure 1.9. The molecular structure of butyl methoxydibenzoylmethane 35 
Figure 1.10. The molecular structure of ethylhexyl triazone and 
diethylhexyl butamido triazone 
37 
Figure 1.11. The molecular structure of polysilicone-15 38 
Figure 1.12. The molecular structure of terephthalylidene dicamphor 
sulfonic acid 
39 
Figure 1.13. The molecular structure of diethylamino hydroxybenzoyl 
hexyl benzoate 
39 
Figure 1.14. The molecular structure of disodium phenyl dibenzimidazole 
tetrasulfonate 
40 
Figure 1.15. The molecular structure of drometrizole trisiloxane 41 
Figure 1.16. The molecular structure of methylene bis-benzotriazolyl 
tetramethylbutylphenol 
42 




Figure 1.18. The molecular structure of ketoprofen, benzophenone-3, 
fenofibrate and tiaprofenic acid 
49 
Figure 2.1. The molecular structure of carprofen 72 
Figure 2.2. Photo-exposed site dermatitis in patient 2 73 
Figure 2.3. Carprofen PPT readings at 72 hours post-irradiation in 
patient 1 
80 
Figure 2.4. Carprofen PPT readings at 24 hours post-irradiation in 
patient 2 
81 
Figure 2.5. Chemical leucoderma in patient 1 83 
Figure 2.6. Carprofen PPT readings at 18 days post-irradiation in 
volunteer 
85 
Figure 3.1. A tube of Neuriplège cream 92 
Figure 3.2. The molecular structure of chlorpromazine and 
chlorproethazine 
93 
Figure 3.3. The absorption spectrum of CPE in the dark and post-






 pilot PPT readings at 24 hours post-irradiation 
in subject 2 
102 
Figure 3.5. Extended PPT readings at 48 hours post-irradiation in 
subject 2 
105 
Figure 3.6. Extended PPT readings at 48 hours post-irradiation in 
subject 1 
106 
Figure 3.7. Extended PPT readings at 48 hours post-irradiation in 
subject 7 
108 
Figure 4.1. The layout of photopatch application in the irritancy study 122 
Figure 4.2. Pilot irritancy study positive reactions at 96 hours in a 
subject 
127 
Figure 4.3. The number of doubtful and weak positive ICDRG graded 
reactions by site and time 
130 
Figure 4.4. The number of subjects with ICDRG reactions graded as 
doubtful (“?+”) or weakly positive (“+”) to the 19 organic 
UV absorbers and 3 controls at any timepoint 
131 
x 
Figure 5.1. The number of products sold by each sunscreen 
manufacturer 
146 
Figure 5.2. The stated SPFs of sunscreens surveyed 147 
Figure 5.3. The number of UV absorbers/reflectors per sunscreen 
product 
147 
Figure 5.4. The percentage of products containing each UV 
absorber/reflector 
149 
Figure 5.5. The percentage of products each UV absorber/reflector was 
present in, comparing 2010 and 2005 survey data 
151 
Figure 6.1. Geographical distribution of the 30 EMCPPTS centres 163 
Figure 6.2. A collage of postmarks and stamps from EMCPPTS centres 172 
Figure 6.3. The number of subjects recruited by each EMCPPTS centre 175 
Figure 6.4. The number of PACD reactions to the 24 test agents and 
petrolatum control 
177 
Figure 6.5 EMCPPTS PPT readings at 24 hours post-irradiation in 
Dundee subject 
178 
Figure 6.6. The PACD reactions recorded to 20 test agents at 24 hours 
post-irradiation 
184 
Figure 6.7. The PACD reactions recorded to 12 test agents at 72 hours 
post-irradiation or later 
186 
Figure 6.8. The number of ACD reactions to 15 test agents 189 
Figure 6.9. Photoaugmentation of ACD reactions to 7 test agents 193 
Figure 6.10. Photoinhibition of ACD reactions to 11 test agents 194 
Figure 6.11. The age distribution of subjects in the EMCPPTS 196 
Figure 6.12. The percentage of subjects with at least one PACD reaction 
and those with at least one ACD reaction, by each age group 
197 
Figure 6.13. The centre locations of PACD reactions to ketoprofen 203 
Figure 6.14. The centre locations of PACD reactions to etofenamate 203 
Figure 6.15. The centre locations of PACD reactions to octocrylene 204 
Figure 6.16. The centre locations of PACD reactions to benzophenone-3 204 
xi 
Figure 6.17. The centre locations of PACD reactions to butyl 
methoxydibenzoylmethane 
205 
Figure 6.18. The centre locations of ACD reactions to methylene bis-
benzotriazolyl tetramethylbutylphenol 
205 
Figure 6.19. Rates of PACD to ketoprofen, etofenamate, octocrylene and 
benzophenone-3 by country 
206 
Figure 6.20. Concomitant PACD reactions to ketoprofen and octocrylene. 208 
Figure 6.21. EMCPPTS reaction to etofenamate at 24 hours post-
irradiation in Dundee subject 
217 
















List of Tables 
  Page 
Table 1.1. Different PPT methodologies reported between the years 
1982 and 2007 
16 
Table 1.2. Synonyms of the19 organic UV absorbers used in the 
EMCPPTS 
26 
Table 1.3. Reports of PACD and ACD to organic UV absorbers 45 
Table 1.4. Reports of PACD and ACD to topical NSAIDs 47 
Table 2.1. The results of PPT to carprofen in patients 1 & 2 78 
Table 3.1. Results of the in-vitro neutral red uptake phototoxicity assay 101 
Table 3.2. Extended study results of PPT to Neuriplège® cream “as is” 
and 10% CPE in petrolatum 
104 
Table 3.3.   Extended study results for PPT to 0.1% CPE in pet, 0.1% 
CPE in water and 0.5% CPE in water from the irradiated sets 
only 
110 
Table 4.1. The 19 organic UV absorbers used in the pilot irritancy 
study 
120 
Table 4.2. The ICDRG scale for grading photopatch test reactions 124 
Table 4.3. The erythema scale for grading photopatch test reactions 124 
Table 4.4. Baseline demographic data of recruited and analysed pilot 
irritancy study subjects 
126 
Table 5.1. The number and percentage of survey products each UV 
absorber/reflector was present in, with protective 
wavelengths 
148 
Table 5.2. The percentage of products each UV absorber/reflector was 
present in, with protective wavelengths, comparing 2010 and 
2005 survey data 
150 
Table 5.3. The number and percentage of lip products each UV 
absorber/reflector was present in, with protective 
wavelengths 
152 
Table 6.1. Recruiting countries, centres and PIs of the EMCPPTS 162 
xiii 
Table 6.2. The EMCPPTS test agents, with concentrations used 167 
Table 6.3. Recruiting centres with number and percentage of PACD 
reactions 
180 
Table 6.4. Agents with ICDRG grade of PACD reactions in the 
irradiated set 
181 
Table 6.5. Agents with COADEX assignations of PACD reactions 182 
Table 6.6. Agents with ICDRG grade of PACD reactions in the 
irradiated set at 24 hours post-irradiation 
185 
Table 6.7. Agents with ICDRG grade of PACD reactions in the 
irradiated set at 72 hours post-irradiation or later 
187 
Table 6.8. Agents with ICDRG grade of ACD reactions 190 
Table 6.9. Agents with COADEX assignations of ACD reactions 191 
Table 6.10. The number and percentage of subjects with at least one 
PACD reaction and those with at least one ACD reaction, in 
each age group 
197 
Table 6.11. The number and percentage of subjects with at least one 
PACD reaction and those with at least one ACD reaction in 
each diagnostic category 
198 
Table 6.12. The diagnoses of subjects in whom a dose <5 Jcm
-2
 was used 
for irradiation 
199 
Table 6.13. The number and percentage of subjects with at least one 
PACD reaction and those with at least one ACD reaction in 
each indication for recruitment category 
200 
Table 6.14. Associations between PACD reactions to ketoprofen, 
octocrylene and benzophenone-3 
207 
Table 6.15. COADEX assignations in the 34 subjects who had 
concomitant PACD reactions to octocrylene and ketoprofen 
209 
Table 6.16. COADEX assignations in the 22 subjects who had 
concomitant PACD reactions to benzophenone-3 and 
ketoprofen 
209 
Table 6.17. COADEX assignations in the 18 subjects who had 




Table 6.18. COADEX assignations in the 15 subjects who had 
concomitant PACD reactions to benzophenone-3, 
octocrylene and ketoprofen 
210 
Table 6.19. Associations between PACD reactions to the five NSAID 
agents 
211 
Table 6.20. COADEX assignations in the 29 subjects who had 
concomitant PACD reactions to ketoprofen and etofenamate 
211 
Table 6.21. PACD reactions to additional agents, with ICDRG grading 
and COADEX relevance 
213 
Table 6.22. ACD reactions to additional agents, with ICDRG grading 
and COADEX relevance 
213 
Table 8.1. The composition of a new European Baseline photopatch 
test series 
259 
Table 8.2. The composition of an “additional” European photopatch 
test series 
263 












List of Abbreviations 
ACD allergic contact dermatitis 
CAD  chronic actinic dermatitis 
CPE chlorproethazine 
CPZ chlorpromazine 
EMCPPTS European multi-centre photopatch test study 
HIC Health Informatics Centre 
ICDRG International Contact Dermatitis Research Group 
INCI International Nomenclature of Cosmetic Ingredients 
IR irritant reaction 
MED minimal erythemal dose 
NSAIDs nonsteroidal anti-inflammatory drugs 
PABA  para-aminobenzoic acid 
PACD photoallergic contact dermatitis 
PI Principal Investigator 
PLE polymorphic light eruption 
PPT photopatch testing 
SPF sun protection factor 
TCSA tetrachlorosalicylanilide 
UK United Kingdom 
USA United States of America 
UV ultraviolet 




Professor James Ferguson for creating the opportunity for me to undertake this 
work in such a productive and renowned department. Also for his inspirational 
guidance and dynamism over the years as my supervisor. 
Dr Sally Ibbotson for her continual support, appraisal and encouragement over the 
years as my co-supervisor. 
Dr Robert Dawe for his invaluable advice on statistical matters and critical 
appraisal of manuscripts. 
Mrs Lynn Fullerton, Mrs Andrea Cochrane and their team of photobiology 
technicians for conducting the photopatch testing and providing photographic 
material. 
All the Principal Investigators and their supporting staff across the 30 centres which 
recruited patients for the EMCPPTS. 
Dr Julie Woods for her laboratory work in the study of chlorproethazine and advice 
regarding all non-clinical issues. 
All the staff members in the Photobiology Unit who volunteered as healthy controls 
in the photopatch testing investigations of carprofen and chlorproethazine. 
Dr Marie-Claude Marguery for donating the Neuriplège
®
 cream and bringing to our 
attention its sunlight-associated adverse cutaneous effects. 
Alison Bell and Chris Hall in the Health Informatics Centre at the University of 
Dundee, for the EMCPPTS proforma data entry and extraction. 
 
Finally, all the patients and healthy volunteers who consented to participate in all 
the photopatch testing studies, making these possible.  
xvii 
Declaration 
I declare that I am the author of this thesis and have, unless otherwise 
acknowledged, performed the major part of the work presented. In cases where 
studies have been undertaken in collaboration, my contribution is described on the 
following page. I declare that all references cited herein have been consulted by me 








I certify that Alastair Carswell Kerr has carried out research under my supervision 
and has fulfilled the conditions of the relevant Ordinance and Regulations for the 




Professor James Ferguson 
xviii 
Contribution to collaborative studies 
I was the primary author of all the studies included in this thesis and wrote the 
thesis as a whole. A list of relevant publications is provided on page xx, which 
contains the names of co-authors of collaborative studies. All studies were co-
conceived by Professor J. Ferguson and myself.  Additionally, for all studies which 
employed photopatch testing in the Photobiology Unit in Dundee, this was 
performed by Mrs Lynn Fullerton and her team of skilled technicians. Otherwise, 
my role in the studies presented in each Chapter, and the contribution of others, is 
given below. 
Chapter 1. Introduction. 
My contribution: sole author. 
Chapter 2. An occupational outbreak of photoallergy to carprofen. 
My contribution: Primary author of the study. Based on parts of an investigative 
study performed by, and report written by, Dr R.S. Dawe. 
Chapter 3. Chlorproethazine: A second photoallergen on the marketplace. 
My contribution: Primary author of the study. Laboratory work performed by and 
co-authored by, Dr J Woods. Investigative idea initially suggested by Dr M-C 
Marguery. 
Chapter 4. A pilot irritancy study of organic ultraviolet absorbers. 
My contribution: Primary author of the study. Statistical calculations conducted by 
Dr R.S.Dawe. Study conducted in collaboration with L’Oreal Research and 
Development Ltd and Chiltern Early Phase Ltd. 
xix 
Chapter 5. A survey of the availability of sunscreen absorbers in the UK. 
My contribution: Study conducted and authored solely by myself. 
Chapter 6. The European multi-centre photopatch test study (EMCPPTS). 
My contribution: Primary author of the study. I also undertook all the operative 
requirements which enabled the project to proceed including protocol refinement, 
application to regulatory bodies and continual liaison with all collaborative 
investigators and the Health Informatics Centre. Data input and extraction 
performed by the Health Informatics Centre team, with data analysis performed by 
myself. Calibration of UV meters performed by Mrs L Fullerton and Prof H 
Moseley.  
Chapter 7. Conducting the EMCPPTS.  
My contribution: sole author. 
Chapter 8. A new European Baseline photopatch test series 
My contribution: sole author. 
Chapter 9. Conclusions and Future Directions. 
My contribution: sole author. 
 
xx 
List of relevant publications 
Relevant peer-reviewed publications are bound in Appendix 4 at the end of the 
thesis. A list of these publications is given below. 
 
The EMCPPTS taskforce (Kerr AC first author of group).  A European Multi-centre 
Photopatch Test Study (EMCPPTS). Br J Dermatol, 2012; 166: 1002-9. 
Kerr AC. A survey of the availability of sunscreen filters in the U.K. Clin Exp 
Dermatol, 2011; 36: 541-3. 
Kerr AC, Becher G, Ibbotson SH, Ferguson J. Action spectrum for etofenamate 
photoallergic contact dermatitis (Contact Point). Contact Dermatitis, 2011; 65: 117-
8. 
Kerr AC, Ferguson J. Photoallergic contact dermatitis (Review). Photoderm, 
Photoimmunol & Photomed, 2010; 26: 56-69. 
Kerr AC, Shareef M, Dawe RS, Ferguson J. Photopatch testing negative in systemic 
quinine phototoxicity (Brief communication). Photoderm, Photoimmunol & 
Photomed, 2010; 26: 151-2. 
Kerr AC, Niklasson B, Dawe RS, Escoffier A-M, Krasteva M, Sanderson B, 
Ferguson J. A double-blind, randomised assessment of the irritant potential of 
sunscreen chemical dilutions used in photopatch testing. Contact Dermatitis, 2009; 
60: 203-9. 
Kerr AC, Woods JA, Ferguson J. Photocontact allergic and phototoxic studies of 
chlorproethazine. Photoderm, Photoimmunol & Photomed 2008; 24: 11-15. 
Kerr AC, Muller F, Ferguson J, Dawe RS. Occupational carprofen photoallergic 
contact dermatitis. Br J Dermatol, 2008; 159: 1303-8. 
xxi 
 Abstract  
Photoallergic contact dermatitis (PACD) is a clinical problem that has often been 
poorly understood and neglected by dermatologists over recent years. This can be 
partly attributed to its investigation by photopatch testing (PPT) falling between the 
expertise of photobiologists and contact dermatitis clinicians. One result of this 
situation was that no European Baseline PPT series had been agreed on. To redress 
this, the European multi centre photopatch test study (EMCPPTS) was conceived to 
provide up to date information on which photoallergens are of greatest clinical 
relevance. Its conduct and results form the core research project of this thesis.  
To enable the EMCPPTS to proceed and its results to be viewed in a wider context, 
the other Chapters of this thesis explore important related aspects of PACD and 
PPT in Europe. The introduction examines the nature of PACD and PPT and 
reviews current photoallergens. Then, the investigation of the two photoallergens 
carprofen and chlorproethazine by PPT is recounted. These studies highlight 
deficiencies within the current European regulatory system for preventing 
photoallergens from reaching the marketplace, as well as providing templates for 
the investigation of new photoallergens in the human environment. 
This is followed by a pilot PPT study which provides new information on the 
optimum non-irritating concentration of the 19 ultraviolet sunscreen absorbers to be 
used in the EMCPPTS. The issue of attempting to determine the photoallergenic 
potential of the EMCPPTS agents with respect to exposure patterns is addressed by 
conducting a sunscreen survey in the UK. The EMCPPTS itself is then detailed, as 
well as the difficulties that can be encountered when conducting a large clinical 
study of this nature. The results from the EMCPPTS and other presented studies 
were shown to be of importance in deciding upon a new European Baseline PPT 
xxii 
series. The process involved in deciding this series, as well as its content are 
described before overall conclusions and possible future studies in the domain of 
PACD and PPT are discussed.  
 
